Compare ENTA & RMNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTA | RMNI |
|---|---|---|
| Founded | 1995 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.6M | 307.1M |
| IPO Year | 2012 | 2015 |
| Metric | ENTA | RMNI |
|---|---|---|
| Price | $13.93 | $3.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $20.40 | $5.50 |
| AVG Volume (30 Days) | 110.8K | ★ 289.1K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.93 | ★ 197.50 |
| EPS | N/A | ★ 0.39 |
| Revenue | $102,814,000.00 | ★ $431,496,000.00 |
| Revenue This Year | $7.76 | $6.02 |
| Revenue Next Year | N/A | $5.50 |
| P/E Ratio | ★ N/A | $9.54 |
| Revenue Growth | ★ 16.48 | 5.33 |
| 52 Week Low | $4.96 | $2.87 |
| 52 Week High | $17.15 | $5.38 |
| Indicator | ENTA | RMNI |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 67.64 |
| Support Level | $13.75 | $3.65 |
| Resistance Level | $15.52 | $3.84 |
| Average True Range (ATR) | 0.68 | 0.12 |
| MACD | 0.11 | 0.05 |
| Stochastic Oscillator | 63.77 | 93.94 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. The company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management, database, and technology software systems. Geographically, the company generates its revenue from the United States of America and the International market.